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Abstract
The prevalence of germ line mutations in non- BRCA1/2 genes associated with 
hereditary breast cancer (BC) is low, and the role of some of these genes in 
BC predisposition and pathogenesis is conflicting. In this study, 5589 consecu-
tive BC index patients negative for pathogenic BRCA1/2 mutations and 2189 
female controls were screened for germ line mutations in eight cancer predis-
position genes (ATM, CDH1, CHEK2, NBN, PALB2, RAD51C, RAD51D, and 
TP53). All patients met the inclusion criteria of the German Consortium for 
Hereditary Breast and Ovarian Cancer for germ line testing. The highest muta-
tion prevalence was observed in the CHEK2 gene (2.5%), followed by ATM 
(1.5%) and PALB2 (1.2%). The mutation prevalence in each of the remaining 
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Introduction
The prevalence of heterozygous BRCA1 and BRCA2 germ 
line mutations and their associated risks for breast cancer 
(BC) and ovarian cancer (OC) have been extensively 
studied [1]. Pathogenic BRCA1 and BRCA2 germ line 
mutations were found in approximately 17% of the index 
patients with BC who met the inclusion criteria of the 
German Consortium for Hereditary Breast and Ovarian 
Cancer (GC- HBOC) for germ line testing [2]. With the 
advent of next- generation sequencing (NGS), germ line 
testing for hereditary BC/OC could be extended beyond 
the analysis of the BRCA1 and BRCA2 genes [3]. However, 
gene panel sequencing and the testing of a number of 
potential risk genes are challenging, as international guide-
lines for the clinical management of patients carrying 
mutations in non- BRCA1/2 genes do not exist. Established 
non- BRCA1/2, BC/OC risk genes are rarely mutated [4–7], 
and data regarding their contribution to BC/OC risk are 
often controversial. Hence, verification is needed before 
the non- BRCA1/2 genes generally included in gene panel 
testing can be treated as confirmed BC/OC risk genes [8, 
9]. Moreover, criteria that predict mutation probabilities 
in non- BRCA1/2 genes are largely unknown and may dif-
fer from those that predict mutation probabilities in BRCA1 
and BRCA2.
The GC- HBOC established multi- gene panel testing in 
2015. In addition to BRCA1 and BRCA2, eight genes were 
defined as “core genes” based on data available at the 
time of the gene panel design, that suggested their asso-
ciation with BC (ATM, CDH1, CHEK2, NBN, PALB2, 
and TP53) or OC (RAD51C and RAD51D) [10–13]. With 
a relative risk of 5.3 (90% CI: 3.0–9.4), deleterious muta-
tions in the PALB2 gene appeared to confer high BC risk 
[14–17]. Lower relative risks were reported for mutations 
in the CHEK2 (3.0, 90% CI: 2.6–3.5) [18, 19] and ATM 
genes (2.8, 90% CI: 2.2–3.7) [3, 20–23]. The NBN gene 
was considered as a BC predisposition gene mainly based 
on the genotyping results of a common founder muta-
tion, c.657_661del, p.(Lys219Asnfs*16). For this variant, 
a meta- analysis of 10 studies revealed a pooled OR of 
2.66 (95% CI: 1.82–3.90; P < .001) [24]. Mutations in 
TP53 and CDH1 are associated with multiple cancer types, 
one of which is BC. For CDH1 mutations, a relative BC 
risk of 6.6 (90% CI: 2.2–19.9; P = .004) was reported 
[25], whereas reliable risk estimates for TP53 mutations 
are missing. Mutations in the RAD51C and RAD51D genes 
have shown clear evidence of an association with OC, 
whereas evidence of an association with BC is limited 
[10, 26, 27]. The aim of this study was to investigate the 
associations of germ line mutations in selected non- 
BRCA1/2 genes with BC risk and BC phenotype in a 
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genes was 0.3% or lower. Using Exome Aggregation Consortium control data, 
we confirm significant associations of heterozygous germ line mutations with 
BC for ATM (OR: 3.63, 95%CI: 2.67–4.94), CDH1 (OR: 17.04, 95%CI: 3.54–82), 
CHEK2 (OR: 2.93, 95%CI: 2.29–3.75), PALB2 (OR: 9.53, 95%CI: 6.25–14.51), 
and TP53 (OR: 7.30, 95%CI: 1.22–43.68). NBN germ line mutations were not 
significantly associated with BC risk (OR:1.39, 95%CI: 0.73–2.64). Due to their 
low mutation prevalence, the RAD51C and RAD51D genes require further in-
vestigation. Compared with control datasets, predicted damaging rare missense 
variants were significantly more prevalent in CHEK2 and TP53 in BC index 
patients. Compared with the overall sample, only TP53 mutation carriers show 
a significantly younger age at first BC diagnosis. We demonstrate a significant 
association of deleterious variants in the CHEK2, PALB2, and TP53 genes with 
bilateral BC. Both, ATM and CHEK2, were negatively associated with triple- 
negative breast cancer (TNBC) and estrogen receptor (ER)- negative tumor phe-
notypes. A particularly high CHEK2 mutation prevalence (5.2%) was observed 
in patients with human epidermal growth factor receptor 2 (HER2)- positive 
tumors.
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sample of 5589 BRCA1/2 negative BC index patients who 
were recruited and counseled at university hospital- based 
centers of the GC- HBOC.
Patients and Methods
Patient sample
All patients met the inclusion criteria of the GC- HBOC 
for germ line testing (Table S1). Of note, the GC- HBOC 
inclusion criteria are not restricted to familial cases and 
also consider patients with early- onset BC (age at first diag-
nosis [AAD] before 36 years), bilateral BC (AAD before 
51 years), and patients affected by BC and OC even in the 
absence of a family history of BC and OC. In the absence 
of a patient with OC in a family, the available BC patient 
with the youngest AAD was defined as the index patient. 
In families with OC, a BC patient was defined as the index 
patient only when DNA derived from the OC patient was 
not available for genetic testing. Overall, 5589 female index 
patients with BC and without a personal history of OC 
were included in this study. All patients were counseled at 
a participating GC- HBOC center. Physicians qualified in 
genetic counseling recorded personal and family BC/OC 
history, information regarding age at first BC diagnosis and 
tumor receptor status. Written informed consent was 
obtained from all patients, and ethical approval was granted 
by the ethics committee of the University of Cologne (07- 
048). All patients were tested negative for pathogenic germ 
line variants in the BRCA1 and BRCA2 genes, including 
large genomic rearrangements (LGRs).
Control sample
Two publicly accessible control datasets (ExAC and 
FLOSSIES) and sequencing data from 2189 geographically 
matched female controls were used in this study (Table 1). 
From the Exome Aggregation Consortium (ExAC) [28], 
we requested a dataset of individuals of European, non- 
Finnish ancestry, excluding samples from The Cancer 
Genome Atlas (TCGA). This dataset comprises a total of 
27,173 samples, which were analyzed by whole exome 
sequencing. The FLOSSIES project provides a dataset of 
7325 women of European American ancestry (https://whi.
color.com). All participating women have remained cancer- 
free until at least 70 years of age. Germ line DNA samples 
of all participants were screened for variants in 27 estab-
lished or suggested BC predisposition genes, including the 
eight selected non- BRCA1/2 genes. In addition, we sequenced 
germ line DNA samples of 2189 female control individuals 
of German descent (geographically matched controls; GMCs) 
by NGS and analyzed these samples for variants in the 
eight selected non- BRCA1/2 genes. Healthy controls were 
recruited by a study on genetic factors of a noncancer, 
age- related phenotype, and a study on civilization diseases. 
The studies were approved by the local ethic committees, 
and all participants gave their written informed consent. 
At the time of blood draw, all GMCs were at least 40 years 
old (mean age 63, range 40–92) and cancer- free.
Gene panel analysis
Genomic DNA was isolated from venous blood samples. NGS 
and data analysis were carried out at each participating center 
using Illumina sequencing platforms, employing either the 
customized TruRisk® (Agilent or Illumina), a customized 
HaloPlex (Agilent, Santa Clara, California, USA), or the 
TruSight™ Cancer Sequencing Panel (Illumina, San Diego, 
California, USA) for target enrichment. All gene panels covered 
the eight selected non- BRCA1/2 core genes. The diagnostic 
pipelines of the labs involved have been successfully tested 
in European Molecular Genetics Quality Network (EMQN) 
schemes. Since LGRs cannot be detected reliably on the basis 
of NGS- data [29], this mutation type was not included in 
this study. All deleterious variants affecting canonical non- 
BRCA1/2 core gene transcripts (ATM, NM_000051.3; CDH1, 
NM_004360.3; CHEK2, NM_007194; NBN, NM_002485.4; 
PALB2, NM_024675.3; RAD51C, NM_058216.2; RAD51D, 
NM_002878.3; TP53, NM_000546.5) were routinely verified 
by Sanger sequencing.
Variant classification
Variant classification was performed in accordance with 
the regulations of the international ENIGMA consortium 
[30] (Evidence- based Network for the Interpretation of 
Germ line Mutant Alleles; https://enigmaconsortium.org; 
version 1.1: 26 March 2015). All genetic variants were 
classified using a five- tier variant classification system as 
proposed by the Unclassified Genetic Variants Working 
Group of the International Agency for Research on Cancer 
(IARC) (deleterious = class 5, likely deleterious = class 4, 
variant of uncertain significance (VUS) = class 3, likely 
benign = class 2, and benign = class 1) [31]. According 
to the ENIGMA regulations [30], variants reported with 
a minor allele frequency (MAF) ≥1% in control reference 
groups (e.g., ExAC excluding TCGA, FLOSSIES) were 
generally considered benign (class 1). For simplification, 
class 4/5 variants were defined as “deleterious variants.” 
To investigate the associations of germ line mutations in 
selected non- BRCA1/2 genes with BC risk, only protein 
truncating variants (PTVs) were considered in patients and 
controls. PTVs were defined as nonsense, frameshift, or 
essential splice- site variants affecting the invariant splice 
sites or the last nucleotide of an exon. As suggested by 
Lilyquist et al., protein truncating variants in the last exon 
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or within the last 55 bp of the penultimate exon were 
classified as VUS, unless a known functional domain was 
disrupted [32]. For the identification of potentially damag-
ing, rare missense variants we employed two in silico 
prediction tools (SIFT and MutationTaster). Missense vari-
ants were defined as potentially damaging when predicted 
deleterious by both tools (Alamut version 2.10; Interactive 
Biosoftware, Rouen, France ) as of 30 November 2017.
Statistical analysis
We performed case–control analyses for the investigation 
of the association of variants with the BC phenotype and 
case–case analyses for comparison of molecular subgroups. 
Univariate logistic regression was performed to estimate 
odds ratios (OR) and 95% confidence intervals (95%CI) 
using SPSS Statistics, Version 25 (IBM, Armonk, New 
York, USA). Fisher’s exact test and the Student’s t- test 
(for age- related analysis) were used to calculate levels of 
significance, with P- values <0.05 considered significant.
Results
Associations of protein truncating variants 
in the selected core genes with BC
Detailed information on the patient sample is given in 
Table 1. Only protein truncating variants (PTVs) were 
considered to investigate the associations of germ line 
mutations in selected non- BRCA1/2 genes with BC risk 
in patients and controls. A list of all PTVs identified in 
the study sample is provided in Table S2. Among 5589 
index patients with BC, 274 patients (4.9%) carried PTVs 
in the selected non- BRCA1/2 genes. The overall occurrence 
of PTVs in the selected core genes was markedly lower 
in all three control datasets compared with BC index 
patients. In the ExAC control dataset, 389 out of 27,173 
individuals (1.4%) carried PTVs, which was comparable 
to the hypernormal control datasets FLOSSIES (67 of 7325 
women, 0.9%) and GMCs (33 of 2189 women, 1.5%). 
When comparing mutation prevalence in BC index patients 
with ExAC data on a gene- specific level, significant asso-
ciations were observed for ATM (OR: 3.63, 95% CI 
2.67–4.94; P < .0001), CHEK2 (OR: 2.93, 95% CI 2.29–3.75; 
P < .0001), PALB2 (OR: 9.53, 95% CI 6.25–14.51; 
P < .0001), CDH1 (OR: 17.04, 95% CI 3.54–82; P < .0001), 
and TP53 (OR: 7.30, 95% CI 1.22–43.68; P = .038) 
(Table 2). In contrast, we did not observe significant 
associations between PTVs in the NBN gene and BC (OR: 
1.39, 95% CI 0.73–2.64; P = .363). When comparing the 
PTV prevalence in BC index patients with hypernormal 
controls (FLOSSIES, GMCs), higher ORs were observed 
for ATM, CHEK2, and PALB2 than were observed in 
comparison with ExAC data (Table 2). Again, no associa-
tion between PTVs in the NBN gene and BC was observed. 
In contrast to the aforementioned genes, the analysis of 
RAD51C and RAD51D revealed ambiguous results. For 
RAD51C, a significant association with BC was observed 
when comparing PTV prevalence with FLOSSIES but not 
when compared with ExAC data or GMCs (Table 2). For 
RAD51D, ORs of 3.04 (vs. ExAC data) and 3.28 (vs. 
FLOSSIES) were observed, though both comparisons did 
not reach levels of significance (Table 2).
Deleterious variants in non- BRCA1/2 genes 
in the overall patient sample
Overall, heterozygous deleterious variants in at least one 
of the eight non- BRCA1/2 core genes were present in 
Table 1. Clinical and BC tumor characteristics observed in the study 
sample (n = 5589) and information on control reference groups 
(Geographically matched controls, GMCs; FLOSSIES, Female controls of 
European American ancestry, older than age 70 years and cancer- free; 
ExAC, Non- Finnish Europeans from the Exome Aggregation Consortium, 
excluding TCGA data) used in this study.
Number %
BC index patients, overall 5589 100.0
Unilateral BC 4960 88.7
Bilateral BC 629 11.3
Without OC family history 4655 83.3
With OC family history 934 16.7







Data not available 49 0.9
BC index patients, ER/PR/
HER2 status available
3104 100.0
ER- positive 2355 75.9
ER- negative 749 24.1
PR- positive 2188 70.5
PR- negative 916 29.5
HER2- positive 657 21.2
HER2- negative 2447 78.8
TNBC 482 15.5
Non- TNBC 2622 84.5






Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, 
human epidermal growth factor receptor 2; TNBC, triple- negative 
breast cancer.
*The age at first diagnosis (AAD) was available for 5540 of 5589 BC 
index patients (mean AAD 46.7 years, range 17–92 years).
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339 of the 5589 BC index patients (6.1%, Table 3). The 
highest prevalence of deleterious variants was observed 
in the CHEK2 gene (138 carriers, 2.5%), followed by ATM 
(81 carriers, 1.4%) and PALB2 (68 carriers, 1.2%). The 
prevalence of deleterious variants in the CDH1, NBN, 
RAD51C, RAD51D, and TP53 genes in the overall patient 
sample was 0.3% or lower for each gene (Table 3). Overall, 
147 distinct deleterious variants were identified in 339 
patients, of which 45 were recurrent (Table). With a car-
rier frequency of 1.4%, the c.1100del founder variant in 
the CHEK2 gene was the most prevalent deleterious variant 
observed (Table 3).
Deleterious variants in non- BRCA1/2 genes 
according to personal and family history of 
cancer
Among the 5589 BC index patients, 629 were affected by 
bilateral BC. In this subgroup, 8.3% of patients (52 of 
629) carried a deleterious variant in at least one of the 
eight selected genes. This was significantly higher than 
the prevalence of deleterious variants in the 4960 BC 
index patients affected by unilateral BC (5.8%, 289 in 
4960; P = .021). On a gene- specific level, the CHEK2 
c.1000del founder variant (2.5% vs. 1.3%; P = .018), 
deleterious variants in the PALB2 gene (2.2% vs. 1.1%; 
P = .020), and deleterious variants in the TP53 gene 
(0.79% vs. 0.24%; P = .035) were significantly associated 
with bilateral BC (Table 3). Of the 5589 BC index patients, 
934 reported a family history of OC. The prevalence of 
deleterious variants was not significantly different in BC 
index patients with a family history of OC versus the 
4655 BC index patients who had no family history of 
OC (data not shown).
Deleterious variants in non- BRCA1/2 genes 
according to age at first diagnosis of BC
In a gene- specific analysis, only patients carrying deleterious 
TP53 variants showed a younger mean age at first BC 
diagnosis (TP53: 39.7 years, range 23–71 years) compared 
with the overall sample (46.7 years, range 17–92 years), 
with differences reaching levels of significance (P = .004, 
Student’s t- test, Table 4). For example, 52.9% (9 of 17) 
of the TP53 mutation carriers showed an age at first BC 
diagnosis below the age of 40 years compared with 26.0% 
(1440 of 5540) of the BC index patients overall (P = .021, 
Table 4). Overall, no significant difference in age at first 
BC diagnosis was observed between patients carrying del-
eterious variants and the overall sample (Table 4).
Table 2. Prevalence of protein truncating variants (PTVs) in eight non- BRCA1/2 cancer predisposition genes in 5589 BC index patients compared with 
control datasets (ExAC, FLOSSIES, and GMCs). Percentages of individuals carrying a mutation in the respective datasets are shown in parentheses.
Gene
BC 
n = 5589 
(%)
ExAC 
n = 27,173 
(%)
FLOSSIES 
n = 7325 
(%)
GMCs 
n = 2189 
(%)
BC vs. ExAC 
OR (95% CI, P*)
BC vs. FLOSSIES 
OR (95% CI, P*)
BC vs. GMCs 
OR (95% CI, P*)






CDH1 7 (0.13) 2 (0.01) 0 (0.0) 0 (0.0) 17.04 (3.54–82, 
<0.0001)
n.a. (n.a., 0.0028) n.a. (n.a., 0.2020)


















PALB2 64 (1.15) 33 (0.12) 7 (0.10) 2 (0.09) 9.53 (6.25–14.51, 
<0.0001)















TP53 3 (0.05) 2 (0.01) 0 (0.0) 0 (0.0) 7.30 (1.22–43.68, 
0.0378)
n.a. (n.a., 0.0810) n.a. (n.a., 0.5640)
PTVs 274 389 67 33
Carriers# 272 (4.87) 389 (1.43) 67 (0.91) 33 (1.51)
OR, odds ratio; CI, confidence interval.
*Fisher’s exact test.
#Two patients carried two PTVs (ATM and CHEK2; NBN and RAD51C).
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Deleterious variants in BC index patients 
according to ER/PR/HER2 status
Information regarding hormone receptor (ER/PR) and 
HER2 status was available for a subgroup of 3104 of the 
5589 BC index cases. Within this subgroup, 482 showed 
a triple- negative breast cancer (TNBC) phenotype (15.5%, 
Table 1). The mutation prevalence in patients with ER- 
positive BC was significantly increased in patients with 
ER- negative tumors (7.3% vs. 4.7%, P = .014; Table 5). 
In a gene- specific analysis, this difference was highest in 
the ATM (1.83% vs. 0.53%, P = .009; Table 5) and CHEK2 
genes (3.2% vs. 1.9%, P = .060; Table 5). The overall 
prevalence of deleterious variants was not significantly 
different when stratified by PR or HER2 status (Table 5). 
On a gene- specific level, however, a particularly high 
CHEK2 mutation prevalence was observed in patients with 
HER2- positive tumors compared with patients with HER2- 
negative tumors (5.2% vs. 2.3%; P < .001; Table 5). TNBC 
Table 3. Deleterious variants in eight non- BRCA1/2 core genes identified in 5589 BC index patients. Total numbers of patients carrying deleterious 
variants in each gene are given. Percentages of patients carrying a deleterious variant in the respective subgroup are shown in parentheses.
Gene
BC index patients
All, n = 5589 (%)
Bilateral BC,  
n = 629 (%) Unilateral BC, n = 4960 (%)
Bilateral vs. unilateral BC 
OR (95% CI, P*)
ATM 81 (1.45) 10 (1.59) 71 (1.43) 1.11 (0.57–2.17, 0.7229)
CDH1 8 (0.14) 1 (0.16) 7 (0.14) 1.13 (0.14–9.17, 1.0000)
CHEK2* 138 (2.47) 20 (3.18) 118 (2.38) 1.35 (0.83–2.18, 0.2196)
CHEK2, c.1100del 79 (1.41) 16 (2.54) 63 (1.27) 2.03 (1.17–3.53, 0.0180)
NBN 12 (0.21) 0 (0.00) 12 (0.24) n.a. (n.a., 0.3830)
PALB2 68 (1.22) 14 (2.23) 54 (1.09) 2.07 (1.14–3.75, 0.0201)
RAD51C 11 (0.20) 1 (0.16) 10 (0.20) 0.79 (0.10–6.17, 1.0000)
RAD51D 6 (0.11) 1 (0.16) 5 (0.10) 1.58 (0.18–13.53, 0.5116)
TP53 17 (0.30) 5 (0.79) 12 (0.24) 3.30 (1.16–9.41, 0.0348)
Deleterious variants 341 52 289 1.46 (1.07–1.98, 0.0211)
Carriers# 339 (6.07) 52 (8.27) 287 (5.79) 1.50 (1.10–2.04, 0.0124)
*The disease- associated CHEK2 variant c.470C>T, p.I157T was classified as a low- risk variant for BC based on a recent meta- analysis including 15,985 
BC cases and 18,609 controls from eight studies (OR: 1.58, 95% CI 1.42–1.75; P < .00001)[37]. In our study, the c.470C>T, p.I157T was heterozy-
gously present in 86 out of 5589 BC index patients (1.54%). In contrast, 44 heterozygous mutation carriers were identified among the 2189 hyper-
normal female controls of German descent analyzed in this study (2.0%). Due to the lack of association with BC in our sample, this variant was not 
considered to be a deleterious mutation in our study.
#Two patients carried two deleterious variants (ATM and CHEK2; NBN and RAD51C). Mutation prevalence showing significant differences according 
to the subgroups (bilateral BC vs. unilateral BC) are shown in bold. n.a. = not applicable.
Table 4. Age at first diagnosis of BC in the overall sample and according to germ line mutation status. Included are patients carrying deleterious vari-
ants in the respective risk gene. Compared with the overall sample, only TP53 mutation carriers showed a significantly younger age at first 
diagnosis.
Gene








<40 years  
(% of carriers)
<50 years  
(% of carriers)
<60 years  
(% of carriers)
Overall* 5540 46.7 46 17–92 1440 (26.0) 3580 (64.6) 4849 (87.5)
ATM 81 45.0 45 27–80 28 (34.6) 58 (71.6) 71 (87.7)
CDH1 8 45.1 43 33–59 3 (37.5) 6 (75.0) 8 (100.0)
CHEK2 138 47.1 46 29–75 35 (25.4) 92 (66.7) 120 (87.0)
NBN 12 46.3 50 33–74 3 (25.0) 6 (50.0) 11 (91.7)
PALB2 68 45.8 46 28–78 20 (29.4) 44 (64.7) 62 (91.2)
RAD51C 11 44.9 48 33–53 4 (36.4) 6 (54.5) 11 (100.0)
RAD51D 6 46.8 49 33–60 1 (16.7) 3 (50.0) 5 (83.3)
TP53 17 39.7 35 23–71 9 (52.9) 14 (82.4) 16 (94.1)
All carriers 339 45.9 45 23–80 94 (27.7) 228 (67.3) 301 (88.8)
*The age at first diagnosis of BC was available for 5540 of 5589 BC index patients.
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predicts a significantly lower mutation probability in the 
selected genes. While deleterious mutations were present 
in 186 of the 2622 patients with non- TNBC (7.1%), only 
20 of the 482 patients with TNBC (4.1%) carried a del-
eterious mutation (P = .017; Table 5). Both the ATM 
and CHEK2 genes showed significantly higher mutation 
rates in patients with non- TNBC versus patients with a 
TNBC tumor phenotype (ATM: 1.7% vs. 0.4%; P = .026; 
CHEK2: 3.3% vs. 0.8%, P = .002; Table 5).
Variants of uncertain significance (VUS) and 
rare missense variants in the overall patient 
sample
In 827 of the 5589 index patients (14.8%; Table S2), we 
identified 421 distinct variants of uncertain significance 
(VUS). Most VUS were missense variants (396 of 421; 
94.1%). Most VUS were present in the ATM gene (affect-
ing 322 of 5589 patients; 5.8%), followed by the CHEK2 
(196 of 5589 patients; 3.5%) and PALB2 genes (76 of 
5589 patients; 1.4%). The vast majority of patients with 
an uncertain genetic report carry a single VUS in the 
selected genes (761 of 829; 91.8%). To examine the poten-
tial association of missense variants in the 8 investigated 
genes with BC risk, we next focused on rare missense 
variants (MAF < 0.1%), which were predicted to be dam-
aging by both, SIFT and MutationTaster (Table S3). 
Compared with ExAC controls, rare CHEK2 and TP53 
missense variants predicted damaging by both tools were 
significantly more prevalent in BC patients (1.43% vs. 
0.71%; P < .0001 and 0.41% vs. 0.18%; P = .002). Prevalence 
of these rare missense variants in ATM, PALB2, RAD51C, 
and RAD51D was only marginally increased in comparison 
with ExAC controls, which differences not reaching levels 
of statistical significance.
Discussion
In our sample of 5589 BC index cases, we confirmed that 
PTVs in the ATM, CDH1, CHEK2, PALB2, and TP53 genes 
increase BC risk. The ORs for the most frequently mutated 
genes (ATM (OR: 3.63, 95% CI 2.67–4.94), CHEK2 (OR: 
2.93, 95% CI 2.29–3.75), and PALB2 (OR: 9.53, 95% CI 
6.25–14.51) are compatible with published data, according 
to a meta- analysis focusing on PTVs [33]. In this meta- 
analysis, an aggregated OR of 3.20 (95% CI 2.04–5.04; 
analysis of 4266 cases and 5566 controls) was calculated 
for ATM, an aggregated OR of 3.25 (95% CI 2.55–4.13, 
analysis of 7263 cases and 13,785 controls) was calculated 
for CHEK2, and an aggregated OR of 21.40 (95% CI 
10.10–45.32, analysis of 5862 cases and 17,453 controls) 
was calculated for PALB2. Based on a recent analysis of 
a large series of BC patients of European ancestry, Couch 
et al. reported ORs of 3.13 (95% CI 2.33–4.23) for ATM, 
2.23 (95% CI 1.85–2.69) for CHEK2, and 7.67 (95% CI 
5.19–11.50) for PALB2 when focusing on PTVs [4]. Similar 
ORs were also observed for these genes in the Australian 
population [9]. For the syndrome- associated genes CDH1 
and TP53, we confirm significant associations with BC, 
though with wide confidence intervals.
In contrast to previous studies focusing on the 
c.657_661del, p.(Lys219Asnfs*16) founder mutation [24], 
Table 5. Deleterious variants in the eight selected non- BRCA1/2 core genes identified in 5589 BC index patients. Total numbers of patients carrying 
deleterious variants in each gene are given. Percentages of patients carrying a mutation in the respective subgroup are shown in parentheses. 
Mutation prevalence showing significant differences according to the subgroups are shown in bold (ER- positive vs. ER- negative; PR- positive vs. PR- 






n = 3104 
(%)
ER- positive 




n = 749 
(%)
PR- positive 












n = 2447 
(%)
Non- TNBC 
n = 2622 
(%)
TNBC 
n = 482 
(%)
ATM 47 (1.51) 43 (1.83) 4 (0.53) 39 (1.78) 8 (0.87) 7 (1.07) 40 (1.63) 45 (1.72) 2 (0.41)
CDH1 7 (0.23) 6 (0.25) 1 (0.13) 4 (0.18) 3 (0.33) 1 (0.15) 6 (0.25) 6 (0.23) 1 (0.21)
CHEK2 90 (2.90) 76 (3.23) 14 (1.87) 70 (3.20) 20 (2.18) 34 (5.18) 56 (2.29) 86 (3.28) 4 (0.83)
CHEK2, 
c.1100del
52 (1.68) 43 (1.83) 9 (1.20) 42 (1.92) 10 (1.09) 20 (3.04) 32 (1.31) 49 (1.87) 3 (0.62)
NBN 5 (0.16) 4 (0.17) 1 (0.13) 3 (0.14) 2 (0.22) 0 (0.00) 5 (0.20) 4 (0.15) 1 (0.21)
PALB2 40 (1.29) 31 (1.32) 9 (1.20) 29 (1.33) 11 (1.20) 4 (0.61) 36 (1.47) 32 (1.22) 8 (1.66)
RAD51C 4 (0.13) 3 (0.13) 1 (0.13) 2 (0.09) 2 (0.22) 1 (0.15) 3 (0.12) 3 (0.11) 1 (0.21)
RAD51D 3 (0.10) 1 (0.04) 2 (0.27) 1 (0.05) 2 (0.22) 0 (0.00) 3 (0.12) 1 (0.04) 2 (0.41)
TP53 10 (0.32) 7 (0.30) 3 (0.40) 8 (0.37) 2 (0.22) 5 (0.76) 5 (0.20) 9 (0.34) 1 (0.21)
Carriers 206 (6.64) 171 (7.26) 35 (4.67) 156 (7.13) 50 (5.46) 52 (7.91) 154 (6.29) 186 (7.09) 20 (4.15)
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we could not confirm NBN as a BC predisposition gene 
(OR: 1.39, 95% CI 0.73–2.64; P = .363; Table 2). This 
is consistent with the panel gene analyses by Couch et al. 
(OR: 1.27, 95% CI 0.81–2.01; P = .32) and Thompson 
et al. (OR: 0.67, 95% CI 0.11–4.0; P = 1.00) [4, 9]. For 
RAD51D mutations, we demonstrated some indication of 
an association with BC (OR: 3.04, 95% CI 0.99–9.30; 
P = .0558), which is compatible with the results obtained 
by Couch et al. using the same control dataset (OR: 2.90, 
95% CI 1.12–7.21; P = .02) [4]. However, these associa-
tions did not reach levels of significance. Thus, we suggest 
that larger collaborative studies are necessary to assess 
the role of RAD51D in BC pathogenesis. The same holds 
true for RAD51C mutations for which we showed an 
elevated prevalence in BC index patients versus hyper-
normal controls but not versus ExAC data (Table 2).
We demonstrated significantly higher mutation preva-
lence in bilateral versus unilateral BC cases, with highest 
differences in CHEK2, PALB2, and TP53 (Table 3). In 
agreement with the data presented here, Couch et al. 
showed that pathogenic variants in CHEK2, PALB2, and 
TP53 were associated with bilateral BC [4]. A young age 
at BC disease onset, a personal or family history of OC, 
and the occurrence of the TNBC tumor phenotype predict 
high mutation probabilities in the BRCA1 gene and to a 
lesser extent in the BRCA2 gene [2]. However, these cri-
teria do not effectively enrich for patients with mutations 
in non- BRCA1/2 genes. In this investigation, age at first 
BC diagnosis did not significantly predict mutation prob-
abilities overall, with the exception of TP53 mutations, 
which is well in line with published data [34, 35]. The 
mutation prevalence in non- BRCA1/2 genes stratified by 
age likewise did not differ markedly in the studies of 
Thompson et al. and Buys et al. [5, 9]. Of note, the 
subgroup of patients with TNBC, a tumor phenotype 
closely associated with a high BRCA1 mutation prevalence 
[35, 36], showed lower mutation probabilities in non- 
BRCA1/2 genes, especially for ATM and CHEK2 mutations, 
we identified a negative association with this subtype 
(Table 5). Similar results were observed by Buys et al., 
demonstrating significantly lower mutation probabilities 
for both genes in patients with TNBC versus other sub-
types [5]. Deleterious ATM and CHEK2 mutations were 
particularly frequent in ER- positive tumors, while CHEK2 
mutations were also frequently found in HER2- positive 
tumors.
Our study confirmed the benefit of multi- gene testing 
for risk assessment in BC/OC families. Here, we identified 
deleterious variants in validated BC predisposition genes 
(ATM, CDH1, CHEK2, PALB2, and TP53) in 312 of 5589 
BC index cases, enabling the offer of predictive testing 
and adjusted surveillance programs in these families. Of 
note, we identified a high prevalence of VUS which is 
still a major drawback of multi- gene testing in a diagnostic 
setting.
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